NCT01049373View on ClinicalTrials.gov

Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain

PHASE3CompletedINTERVENTIONAL

Enrollment

221

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Low Back Pain

Interventions

DRUG

HDC

(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.

DRUG

Placebo solution

10 drops, t.i.d, 15 weeks

Trial Locations (1)

D-45527

Department of Naturopathy, Blankenstein Hospital, Hattingen

All Listed Sponsors

lead

Pascoe Pharmazeutische Praeparate GmbH

INDUSTRY

NCT01049373 - Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain | Biotech Hunter | Biotech Hunter